Skip to content
Menu

Morgan Stanley Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $103

Benzinga Newsdesk 2 days ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Morgan Stanley analyst Matthew Harrison maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and lowers the price target from $119 to $103.

Morgan Stanley analyst Matthew Harrison maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and lowers the price target from $119 to $103.

Read at benzinga.com